bcma/gprc5d double car-t
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 27, 2023 (NCT05998928)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
- G-protein coupled receptor family C group 5 member DImmunity, passive
immunity, passive - gprc5d
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06068400 | N/A | Sep 13, 2023 | Guangzhou Bio-gene Technology Co., Ltd., Shenzhen Qianhai Shekou Free Trade Zone Hospital |
| NCT05998928 | Phase 2 | Jul 27, 2023 | Guangzhou Bio-gene Technology Co., Ltd., Huazhong University of Science and Technology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 2 | 1 | 2 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Shenzhen Qianhai Shekou Free Trade Zone Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1